Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 T-lymphocyte counts

about

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 T-lymphocyte counts

Item

http://www.wikidata.org/entity/Q58692202

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в липні 2018

@uk

name

Phase II study of ERC1671 plus ...... s with CD4 T-lymphocyte counts

@en

Phase II study of ERC1671 plus ...... s with CD4 T-lymphocyte counts

@nl

type

Item

label

Phase II study of ERC1671 plus ...... s with CD4 T-lymphocyte counts

@en

Phase II study of ERC1671 plus ...... s with CD4 T-lymphocyte counts

@nl

prefLabel

Phase II study of ERC1671 plus ...... s with CD4 T-lymphocyte counts

@en

Phase II study of ERC1671 plus ...... s with CD4 T-lymphocyte counts

@nl

P1476

Phase II study of ERC1671 plus ...... s with CD4 T-lymphocyte counts

@en

P2093

Ankie Strik

http://www.w3.org/2001/XMLSchema#string

Apostolos Stathopoulos

http://www.w3.org/2001/XMLSchema#string

Axel H Schönthal

http://www.w3.org/2001/XMLSchema#string

Beverly D Fu

http://www.w3.org/2001/XMLSchema#string

Chrystel Pretto

http://www.w3.org/2001/XMLSchema#string

Daniela A Bota

http://www.w3.org/2001/XMLSchema#string

Florence M Hofman

http://www.w3.org/2001/XMLSchema#string

Frank Pk Hsu

http://www.w3.org/2001/XMLSchema#string

Jinah Chung

http://www.w3.org/2001/XMLSchema#string

Jose A Carrillo

http://www.w3.org/2001/XMLSchema#string

P2860

The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review

An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma

Nonsurgical treatment of recurrent glioblastoma

Immunotherapy for brain cancer: recent progress and future promise

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.

Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.

P304

CNS22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/CNS-2018-0009

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Raphael Zidovetzki

P577

2018-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30157683

http://www.w3.org/2001/XMLSchema#string

P921

placebo

bevacizumab

P932

6200061

http://www.w3.org/2001/XMLSchema#string